Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin
Abstract The pharmacokinetics of vinblastine were studied in 16 patients with non-small cell lung cancer after a bolus intravenous dose of 3 mg/m2 given before or after cisplatin (100 mg/m2). Venous blood was collected at 0, 10, and 36 hr for analysis by radio-immunoassay. The mean plasma vinblastin...
Gespeichert in:
| Veröffentlicht in: | Cancer investigation 1999, Vol.17 (7), p.479-485 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 485 |
|---|---|
| container_issue | 7 |
| container_start_page | 479 |
| container_title | Cancer investigation |
| container_volume | 17 |
| creator | Links, Matthew Watson, Shaun Lethlean, Keith Aherne, Wynne Kirsten, Fred Clarke, Stephen Law, Matthew Friedlander, Michael Galettis, Peter McKeage, Mark J. |
| description | Abstract
The pharmacokinetics of vinblastine were studied in 16 patients with non-small cell lung cancer after a bolus intravenous dose of 3 mg/m2 given before or after cisplatin (100 mg/m2). Venous blood was collected at 0, 10, and 36 hr for analysis by radio-immunoassay. The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1). Plasma vinblastine concentrations in patients given cisplatin were higher than previously reported in patients given vinblastine alone. Patients with plasma vinblastine concentrations less than 2.75 ng/ml at 10 hr experienced less severe neutropenia (37% fall in neutrophil count; 95% CI, 18-55) than those with levels greater than 2.75 ng/ml (69% fall in neutrophil count; 95% CI, 62-77). In conclusion. the pharmacokinetics of vinblastine predict the severity of neutropenia and may be altered when given in conjunction with cisplatin. |
| doi_str_mv | 10.3109/07357909909032857 |
| format | Article |
| fullrecord | <record><control><sourceid>informahealthcare_pasca</sourceid><recordid>TN_cdi_pascalfrancis_primary_1990633</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_3109_07357909909032857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-3c302b86540e23ec1c500a33f127172e241639a851e3295215ce29bd9f8c742e3</originalsourceid><addsrcrecordid>eNp9kF1LwzAUhoMobk5_gDeSC2-r-WiWFr2RolMYOvAD70qapTYzS0eSOfbvzehERRBCwiHPczjnBeAYozOKUX6OOGU8R3k8iJKM8R3Qx4ySJMU52QX9zX8SAd4DB97PEMIZ4Wwf9DBiOItMH7y-aFsZ4YO2Ck4a4eZCtu-xCFp6qC2ciKCVDR6udGjgfWuTx7kwBhYqXuOlfYOFsFI5ONIfysJC-4WJij0Ee7UwXh1t3wF4vrl-Km6T8cPorrgaJzKlOCRUUkSqbMhSpAhVEkuGkKC0xoRjThRJ8ZDmImNYUZIzgplUJK-meZ1JnhJFBwB3faVrvXeqLhdOz4VblxiVm5TKPylF56RzFstqrqY_jC6WCJxuAeGlMLWLK2r_zcVeQ0ojdtlh2tZtTG7VOjMtg1ib1n059L8xLn7pjRImNFI4Vc7apbMxtn-W-ATM7JM3</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin</title><source>MEDLINE</source><source>Taylor & Francis Medical Library - CRKN</source><source>Taylor & Francis Journals Complete</source><creator>Links, Matthew ; Watson, Shaun ; Lethlean, Keith ; Aherne, Wynne ; Kirsten, Fred ; Clarke, Stephen ; Law, Matthew ; Friedlander, Michael ; Galettis, Peter ; McKeage, Mark J.</creator><creatorcontrib>Links, Matthew ; Watson, Shaun ; Lethlean, Keith ; Aherne, Wynne ; Kirsten, Fred ; Clarke, Stephen ; Law, Matthew ; Friedlander, Michael ; Galettis, Peter ; McKeage, Mark J.</creatorcontrib><description>Abstract
The pharmacokinetics of vinblastine were studied in 16 patients with non-small cell lung cancer after a bolus intravenous dose of 3 mg/m2 given before or after cisplatin (100 mg/m2). Venous blood was collected at 0, 10, and 36 hr for analysis by radio-immunoassay. The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1). Plasma vinblastine concentrations in patients given cisplatin were higher than previously reported in patients given vinblastine alone. Patients with plasma vinblastine concentrations less than 2.75 ng/ml at 10 hr experienced less severe neutropenia (37% fall in neutrophil count; 95% CI, 18-55) than those with levels greater than 2.75 ng/ml (69% fall in neutrophil count; 95% CI, 62-77). In conclusion. the pharmacokinetics of vinblastine predict the severity of neutropenia and may be altered when given in conjunction with cisplatin.</description><identifier>ISSN: 0735-7907</identifier><identifier>EISSN: 1532-4192</identifier><identifier>DOI: 10.3109/07357909909032857</identifier><identifier>PMID: 10518192</identifier><identifier>CODEN: CINVD7</identifier><language>eng</language><publisher>New York, NY: Informa UK Ltd</publisher><subject>Aged ; Antineoplastic agents ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - adverse effects ; Antineoplastic Agents, Phytogenic - pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - metabolism ; Chemotherapy ; Cisplatin - administration & dosage ; Drug Administration Schedule ; Female ; Humans ; Injections, Intravenous ; Leukocyte Count - drug effects ; Lung Neoplasms - drug therapy ; Lung Neoplasms - metabolism ; Male ; Medical sciences ; Middle Aged ; Neoplasm Staging ; Neutrophils - drug effects ; Pharmacology. Drug treatments ; Radioimmunoassay ; Vinblastine - administration & dosage ; Vinblastine - adverse effects ; Vinblastine - pharmacokinetics ; Vinblastine - therapeutic use</subject><ispartof>Cancer investigation, 1999, Vol.17 (7), p.479-485</ispartof><rights>1999 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 1999</rights><rights>1999 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-3c302b86540e23ec1c500a33f127172e241639a851e3295215ce29bd9f8c742e3</citedby><cites>FETCH-LOGICAL-c431t-3c302b86540e23ec1c500a33f127172e241639a851e3295215ce29bd9f8c742e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.tandfonline.com/doi/pdf/10.3109/07357909909032857$$EPDF$$P50$$Ginformahealthcare$$H</linktopdf><linktohtml>$$Uhttps://www.tandfonline.com/doi/full/10.3109/07357909909032857$$EHTML$$P50$$Ginformahealthcare$$H</linktohtml><link.rule.ids>314,776,780,4010,27900,27901,27902,59620,59726,60409,60515,61194,61229,61375,61410</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1990633$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10518192$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Links, Matthew</creatorcontrib><creatorcontrib>Watson, Shaun</creatorcontrib><creatorcontrib>Lethlean, Keith</creatorcontrib><creatorcontrib>Aherne, Wynne</creatorcontrib><creatorcontrib>Kirsten, Fred</creatorcontrib><creatorcontrib>Clarke, Stephen</creatorcontrib><creatorcontrib>Law, Matthew</creatorcontrib><creatorcontrib>Friedlander, Michael</creatorcontrib><creatorcontrib>Galettis, Peter</creatorcontrib><creatorcontrib>McKeage, Mark J.</creatorcontrib><title>Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin</title><title>Cancer investigation</title><addtitle>Cancer Invest</addtitle><description>Abstract
The pharmacokinetics of vinblastine were studied in 16 patients with non-small cell lung cancer after a bolus intravenous dose of 3 mg/m2 given before or after cisplatin (100 mg/m2). Venous blood was collected at 0, 10, and 36 hr for analysis by radio-immunoassay. The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1). Plasma vinblastine concentrations in patients given cisplatin were higher than previously reported in patients given vinblastine alone. Patients with plasma vinblastine concentrations less than 2.75 ng/ml at 10 hr experienced less severe neutropenia (37% fall in neutrophil count; 95% CI, 18-55) than those with levels greater than 2.75 ng/ml (69% fall in neutrophil count; 95% CI, 62-77). In conclusion. the pharmacokinetics of vinblastine predict the severity of neutropenia and may be altered when given in conjunction with cisplatin.</description><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents, Phytogenic - administration & dosage</subject><subject>Antineoplastic Agents, Phytogenic - adverse effects</subject><subject>Antineoplastic Agents, Phytogenic - pharmacokinetics</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - metabolism</subject><subject>Chemotherapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Leukocyte Count - drug effects</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - metabolism</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neutrophils - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Radioimmunoassay</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - adverse effects</subject><subject>Vinblastine - pharmacokinetics</subject><subject>Vinblastine - therapeutic use</subject><issn>0735-7907</issn><issn>1532-4192</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kF1LwzAUhoMobk5_gDeSC2-r-WiWFr2RolMYOvAD70qapTYzS0eSOfbvzehERRBCwiHPczjnBeAYozOKUX6OOGU8R3k8iJKM8R3Qx4ySJMU52QX9zX8SAd4DB97PEMIZ4Wwf9DBiOItMH7y-aFsZ4YO2Ck4a4eZCtu-xCFp6qC2ciKCVDR6udGjgfWuTx7kwBhYqXuOlfYOFsFI5ONIfysJC-4WJij0Ee7UwXh1t3wF4vrl-Km6T8cPorrgaJzKlOCRUUkSqbMhSpAhVEkuGkKC0xoRjThRJ8ZDmImNYUZIzgplUJK-meZ1JnhJFBwB3faVrvXeqLhdOz4VblxiVm5TKPylF56RzFstqrqY_jC6WCJxuAeGlMLWLK2r_zcVeQ0ojdtlh2tZtTG7VOjMtg1ib1n059L8xLn7pjRImNFI4Vc7apbMxtn-W-ATM7JM3</recordid><startdate>1999</startdate><enddate>1999</enddate><creator>Links, Matthew</creator><creator>Watson, Shaun</creator><creator>Lethlean, Keith</creator><creator>Aherne, Wynne</creator><creator>Kirsten, Fred</creator><creator>Clarke, Stephen</creator><creator>Law, Matthew</creator><creator>Friedlander, Michael</creator><creator>Galettis, Peter</creator><creator>McKeage, Mark J.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>1999</creationdate><title>Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin</title><author>Links, Matthew ; Watson, Shaun ; Lethlean, Keith ; Aherne, Wynne ; Kirsten, Fred ; Clarke, Stephen ; Law, Matthew ; Friedlander, Michael ; Galettis, Peter ; McKeage, Mark J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-3c302b86540e23ec1c500a33f127172e241639a851e3295215ce29bd9f8c742e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents, Phytogenic - administration & dosage</topic><topic>Antineoplastic Agents, Phytogenic - adverse effects</topic><topic>Antineoplastic Agents, Phytogenic - pharmacokinetics</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - metabolism</topic><topic>Chemotherapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Leukocyte Count - drug effects</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - metabolism</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neutrophils - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Radioimmunoassay</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - adverse effects</topic><topic>Vinblastine - pharmacokinetics</topic><topic>Vinblastine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Links, Matthew</creatorcontrib><creatorcontrib>Watson, Shaun</creatorcontrib><creatorcontrib>Lethlean, Keith</creatorcontrib><creatorcontrib>Aherne, Wynne</creatorcontrib><creatorcontrib>Kirsten, Fred</creatorcontrib><creatorcontrib>Clarke, Stephen</creatorcontrib><creatorcontrib>Law, Matthew</creatorcontrib><creatorcontrib>Friedlander, Michael</creatorcontrib><creatorcontrib>Galettis, Peter</creatorcontrib><creatorcontrib>McKeage, Mark J.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Links, Matthew</au><au>Watson, Shaun</au><au>Lethlean, Keith</au><au>Aherne, Wynne</au><au>Kirsten, Fred</au><au>Clarke, Stephen</au><au>Law, Matthew</au><au>Friedlander, Michael</au><au>Galettis, Peter</au><au>McKeage, Mark J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin</atitle><jtitle>Cancer investigation</jtitle><addtitle>Cancer Invest</addtitle><date>1999</date><risdate>1999</risdate><volume>17</volume><issue>7</issue><spage>479</spage><epage>485</epage><pages>479-485</pages><issn>0735-7907</issn><eissn>1532-4192</eissn><coden>CINVD7</coden><abstract>Abstract
The pharmacokinetics of vinblastine were studied in 16 patients with non-small cell lung cancer after a bolus intravenous dose of 3 mg/m2 given before or after cisplatin (100 mg/m2). Venous blood was collected at 0, 10, and 36 hr for analysis by radio-immunoassay. The mean plasma vinblastine concentration at 10 hr was similar when vinblastine was given before (4.8 ng/ml; 95% CI, 3.2-6.3) or after cisplatin (4.9 ng/ml; 95% CI, 2.7-7.1). Plasma vinblastine concentrations in patients given cisplatin were higher than previously reported in patients given vinblastine alone. Patients with plasma vinblastine concentrations less than 2.75 ng/ml at 10 hr experienced less severe neutropenia (37% fall in neutrophil count; 95% CI, 18-55) than those with levels greater than 2.75 ng/ml (69% fall in neutrophil count; 95% CI, 62-77). In conclusion. the pharmacokinetics of vinblastine predict the severity of neutropenia and may be altered when given in conjunction with cisplatin.</abstract><cop>New York, NY</cop><pub>Informa UK Ltd</pub><pmid>10518192</pmid><doi>10.3109/07357909909032857</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0735-7907 |
| ispartof | Cancer investigation, 1999, Vol.17 (7), p.479-485 |
| issn | 0735-7907 1532-4192 |
| language | eng |
| recordid | cdi_pascalfrancis_primary_1990633 |
| source | MEDLINE; Taylor & Francis Medical Library - CRKN; Taylor & Francis Journals Complete |
| subjects | Aged Antineoplastic agents Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Chemotherapy Cisplatin - administration & dosage Drug Administration Schedule Female Humans Injections, Intravenous Leukocyte Count - drug effects Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Male Medical sciences Middle Aged Neoplasm Staging Neutrophils - drug effects Pharmacology. Drug treatments Radioimmunoassay Vinblastine - administration & dosage Vinblastine - adverse effects Vinblastine - pharmacokinetics Vinblastine - therapeutic use |
| title | Vinblastine Pharmacokinetics in Patients with Non-Small Cell Lung Cancer Given Cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T13%3A51%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-informahealthcare_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vinblastine%20Pharmacokinetics%20in%20Patients%20with%20Non-Small%20Cell%20Lung%20Cancer%20Given%20Cisplatin&rft.jtitle=Cancer%20investigation&rft.au=Links,%20Matthew&rft.date=1999&rft.volume=17&rft.issue=7&rft.spage=479&rft.epage=485&rft.pages=479-485&rft.issn=0735-7907&rft.eissn=1532-4192&rft.coden=CINVD7&rft_id=info:doi/10.3109/07357909909032857&rft_dat=%3Cinformahealthcare_pasca%3E10_3109_07357909909032857%3C/informahealthcare_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/10518192&rfr_iscdi=true |